GlassScriptPhysician profile
Mary Mallappallil
NPI 1578586392
$1,026.13
in general payments reported to CMS, 2019-2025
13 companies · $42.34 in 2025
The $42.34 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $169 · 2021: $50.44 · 2022: $256 · 2023: $284 · 2024: $76.57 · 2025: $42.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $268 · Travel and Lodging: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $267.94 |
| Travel and Lodging | $134.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $403.50 | 2022-2023 | Corevalve Evolut R |
| Astrazeneca Pharmaceuticals LP | $145.65 | 2020-2022 | |
| Fresenius USA Marketing, INC. | $124.95 | 2019 | |
| Vifor Pharma, INC. | $77.59 | 2020-2022 | |
| Biotronik INC. | $68.90 | 2020-2021 | |
| Glaxosmithkline, LLC. | $51.13 | 2024 | Nucala, Benlysta, Jesduvroq |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.25 | 2020 | |
| Amgen INC. | $25.44 | 2024 | Parsabiv, Tavneos |
| Cormedix INC. | $25.00 | 2025 | Defencath |
| Opko Pharmaceuticals, LLC | $23.77 | 2020 | |
| Janssen Pharmaceuticals, INC | $22.61 | 2019 | |
| Ardelyx, INC. | $17.34 | 2025 | Ibsrela |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Mallappallil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.